A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 432 participants.

Also called NCT06834932

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 432 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06834932
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Hong Kong SAR China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06834932. Randomized; triple masking; primary purpose treatment. Start 2024-12-06 (actual); primary completion 2027-02-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
Condition
Dyslipidaemia
Intervention (Drug)
Placebo
Intervention (Drug)
Rosuvastatin Dose 1
Intervention (Drug)
Rosuvastatin dose 2
Intervention (Drug)
AZD0780
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06834932
Content hash
2f89cb0fadc29e0472110b7109fea40ec24d8679376e7f1fae60dac7749393e3